A consensus on the diagnosis and treatment of acromegaly complications

Pituitary

Volumn 16, Issue 3, 2013, Pages 294-302

  Melmed, S ^a   Casanueva, F F ^b   Klibanski, A ^c   Bronstein, M D ^d   Chanson, P ^e,f,g   Lamberts, S W ^h   Strasburger, C J ⁱ   Wass, J A H ^j   Giustina, A ^k  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f BICÊTRE HOSPITAL   (France)

^g INSERM   (France)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j CHURCHILL HOSPITAL   (United Kingdom)

^k UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

Acromegaly; Complications; Consensus; Diagnosis; Treatment

Indexed keywords

CABERGOLINE; GLUCOCORTICOID; PASIREOTIDE; PEGVISOMANT;

ACROMEGALY; ADENOMA; ARTHROPATHY; ARTICLE; BONE DISEASE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; COLON POLYP; COMORBIDITY; CONSENSUS DEVELOPMENT; DIABETES MELLITUS; DISEASE CONTROL; DISEASE SEVERITY; ENDOCRINE DISEASE; FAMILIAL DISEASE; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOPITUITARISM; METABOLIC DISORDER; MORTALITY; NEUROENDOCRINOLOGY; NONHUMAN; ONSET AGE; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; QUALITY OF LIFE; SCREENING TEST; SLEEP DISORDERED BREATHING; SPINE FRACTURE; TREATMENT INDICATION;

EID: 84881373958     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0420-x     Document Type: Article

References (116)

1. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85(2):526-529
2. Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S (2008) Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31(9):820-838
3. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S (2003) Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26(12):1242-1247
4. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141-3148
5. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153(6):737-740
6. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87(9):4054-4058
7. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509-1517
8. Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355(24):2558-2573
9. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93(9):3266-3281
10. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924-926
11. Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, Lombardi G, Colao A (2005) Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol 63(4):470-476
12. Bihan H, Espinosa C, Valdes-Socin H, Salenave S, Young J, Levasseur S, Assayag P, Beckers A, Chanson P (2004) Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 89(11):5308-5313
13. Cannavo S, Almoto B, Cavalli G, Squadrito S, Romanello G, Vigo MT, Fiumara F, Benvenga S, Trimarchi F (2006) Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 91(10):3766-3772
14. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102-152
15. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G (2003) High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 88(7):3196-3201
16. Maffei P, Martini C, Milanesi A, Corfini A, Mioni R, de Carlo E, Menegazzo C, Scanarini M, Vettor R, Federspil G, Sicolo N (2005) Late potentials and ventricular arrhythmias in acromegaly. Int J Cardiol 104(2):197-203
17. van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, van der Wall EE, Smit JW, Romijn JA, Pereira AM (2006) Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 16(2):101-107
18. Andreassen M, Faber J, Kjaer A, Petersen CL, Kristensen LO (2010) Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides. Pituitary 13(4):329-336
19. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89(4):1613-1617
20. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90(7):4081-4086
21. Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, D'Errico A, Kourides I, Burman P, Lombardi G, Colao A (2007) Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 92(2):476-482
22. Davi MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia G (2008) Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 159(5):533-540
23. Colao A, Pivonello R, Grasso LF, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2011) Determinants of cardiac disease in newly diagnosed patients with acromegaly. Results of a 10 year survey study. Eur J Endocrinol 165(5):713-721
24. Colao A, Marek J, Goth MI, Caron P, Kuhn JM, Minuto FM, Weissman NJ (2008) No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab 93(6):2243-2248
25. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P (2007) Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 92(5):1743-1747
26. De Marinis L, Bianchi A, Mazziotti G, Mettimano M, Milardi D, Fusco A, Cimino V, Maira G, Pontecorvi A, Giustina A (2008) The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary 11(1):13-20
27. Maione L, Garcia C, Bouchachi A, Kallel N, Maison P, Salenave S, Young J, Assayag P, Chanson P (2012) No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J Clin Endocrinol Metab. doi: 10.1210/jc.2012-1833
28. Colao A (2012) Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15(1):50-58
29. Lafeber M, Stades AM, Valk GD, Cramer MJ, Teding van Berkhout F, Zelissen PM (2010) Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol 162(4):667-675
30. Erem C, Ersoz HO, Ukinc K, Avunduk AM, Hacihasanoglu A, Kocak M (2006) Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature. Endocrine 30(1):145-149
31. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS, Stewart PM (2010) Mortality in patients with pituitary disease. Endocr Rev 31(3):301-342
32. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 41(1):95-102
33. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94(5):1500-1508
34. Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannavo S, Colao A, Cozzi R, De Marinis L, De Degli Uberti E, Grottoli S, Minuto F, Montini M, Spinello M, Giustina A (2011) Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 164(3):341-347
35. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 95(6):2781-2789
36. Grynberg M, Salenave S, Young J, Chanson P (2010) Female gonadal function before and after treatment of acromegaly. J Clin Endocrinol Metab 95(10):4518-4525
37. Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, Schoenfeld DA, Hayden DL, Wright ME, Woodburn CJ, Klibanski A (2001) Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol 54(2):183-188
38. van Haute FR, Taboada GF, Correa LL, Lima GA, Fontes R, Riello AP, Dominici M, Gadelha MR (2008) Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. Eur J Endocrinol 158(4):459-465
39. Attal P, Chanson P (2010) Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab 95(2):483-495
40. Sze L, Schmid C, Bloch KE, Bernays R, Brandle M (2007) Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 156(3):321-329
41. Grunstein RR, Ho KK, Sullivan CE (1994) Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 121(7):478-483
42. Herrmann BL, Wessendorf TE, Ajaj W, Kahlke S, Teschler H, Mann K (2004) Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 151(3):309-315
43. Ip MS, Tan KC, Peh WC, Lam KS (2001) Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol 55(4):477-483
44. Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P (2008) Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158(3):305-310
45. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93(10):3853-3859
46. Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G, Utz AL, Biller B, Nachtigall L, Loeffler J, Swearingen B, Klibanski A, Miller KK (2009) Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab 94(7):2471-2477
47. Killinger Z, Payer J, Lazurova I, Imrich R, Homerova Z, Kuzma M, Rovensky J (2010) Arthropathy in acromegaly. Rheum Dis Clin North Am 36(4):713-720
48. Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A (2005) Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20(10):1837-1844
49. Wassenaar MJ, Biermasz NR, Hamdy NA, Zillikens MC, van Meurs JB, Rivadeneira F, Hofman A, Uitterlinden AG, Stokkel MP, Roelfsema F, Kloppenburg M, Kroon HM, Romijn JA, Pereira AM (2011) High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 164(4):475-483
50. Podgorski M, Robinson B, Weissberger A, Stiel J, Wang S, Brooks PM (1988) Articular manifestations of acromegaly. Aust N Z J Med 18(1):28-35
51. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90(5):2731-2739
52. Miller A, Doll H, David J, Wass J (2008) Impact of musculoskeletal disease on quality of life in long-standing acromegaly. Eur J Endocrinol 158(5):587-593
53. Colao A, Cannavo S, Marzullo P, Pivonello R, Squadrito S, Vallone G, Almoto B, Bichisao E, Trimarchi F, Lombardi G (2003) Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol 148(1):31-38
54. Wassenaar MJ, Biermasz NR, Bijsterbosch J, Pereira AM, Meulenbelt I, Smit JW, Roelfsema F, Kroon HM, Romijn JA, Kloppenburg M (2011) Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis 70(2):320-325
55. Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A, Pontecorvi A, De Marinis L, Giustina A (2008) Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 93(12):4649-4655
56. Battista C, Chiodini I, Muscarella S, Guglielmi G, Mascia ML, Carnevale V, Scillitani A (2009) Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study. Clin Endocrinol 70(3):378-382
57. Mazziotti G, Gola M, Bianchi A, Porcelli T, Giampietro A, Cimino V, Doga M, Gazzaruso C, De Marinis L, Giustina A (2011) Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40(1):102-108
58. Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G (2008) Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol 14(22):3484-3489
59. Jenkins PJ, Fairclough PD (2002) Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut 51(Suppl 5):V13-V14
60. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5):1570-1595
61. Dworakowska D, Gueorguiev M, Kelly P, Monson JP, Besser GM, Chew SL, Akker SA, Drake WM, Fairclough PD, Grossman AB, Jenkins PJ (2010) Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J Endocrinol 163(1):21-28
62. Ayuk J, Sheppard MC (2008) Does acromegaly enhance mortality? Rev Endocr Metab Disord 9(1):33-39
63. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93(1):61-67
64. Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94(11):4216-4223
65. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189-3202
66. Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE (2007) Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 92(9):3374-3377
67. Cheng S, Grasso L, Martinez-Orozco JA, Al-Agha R, Pivonello R, Colao A, Ezzat S (2012) Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clin Endocrinol 76(2):264-271
68. Caron P, Broussaud S, Bertherat J, Borson-Chazot F, Brue T, Cortet-Rudelli C, Chanson P (2010) Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab 95(10):4680-4687
69. Cozzi R, Attanasio R, Barausse M (2006) Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol 155(2):279-284
70. Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montanana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabate MI, Villa C, Popelier M, Salvatori R, Jennings J, Longas AF, Labarta Aizpun JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95(11):E373-E383
71. Jaffrain-Rea ML, Daly AF, Angelini M, Petrossians P, Bours V, Beckers A (2011) Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications. Exp Rev Endocrinol Metab 6(2):195-214
72. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A, Aaltonen LA (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312(5777):1228-1230
73. Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J, Raffin-Sanson ML (2007) Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 157(1):1-8
74. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M (2008) The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93(6):2390-2401
75. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93(8):2984-2990
76. Mao ZG, Zhu YH, Tang HL, Wang DY, Zhou J, He DS, Lan H, Luo BN, Wang HJ (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 162(4):661-666
77. Shen M, Shou X, Wang Y, Zhang Z, Wu J, Mao Y, Li S, Zhao Y (2010) Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J 57(12):1035-1044
78. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD (2007) Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol 67(2):310-315
79. Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ, Wass JA (2008) Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol 68(6):970-975
80. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P, Beckers A (2005) Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 152(1):61-66
81. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A (2006) Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 29(1):86-93
82. Buchfelder M (2009) Management of aggressive pituitary adenomas: current treatment strategies. Pituitary 12(3):256-260
83. Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247-271
84. Swords FM, Monson JP, Besser GM, Chew SL, Drake WM, Grossman AB, Plowman PN (2009) Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy. Eur J Endocrinol 161(6):819-828
85. Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S (2011) Current management practices for acromegaly: an international survey. Pituitary 14(2):125-133
86. Clemmons DR (2011) Clinical laboratory indices in the treatment of acromegaly. Clin Chim Acta 412(5-6):403-409
87. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83(10):3411-3418
88. Salaun C, Foubert L, Vialatou M, Kujas M, Turpin G (1999) Prognostic factors in the surgical management of acromegaly. Ann Med Interne 150(3):195-198
89. van der Lely AJ, Harris AG, Lamberts SW (1992) The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol 37(2):181-185
90. Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, Sano T, Yoshimoto K, Frank SJ, Ezzat S (2007) A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 67(15):7505-7511
91. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9(2):103-113
92. Kitz K, Knosp E, Koos WT, Korn A (1991) Proliferation in pituitary adenomas: measurement by MAb KI 67. Acta Neurochir Suppl 53:60-64
93. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84(2):761-767
94. Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt- Demasters BK, Wierman ME (2012) Clinical implications of growth hormone-secreting tumor subtypes. Endocrine 42(1):18-28
95. Bando H, Sano T, Ohshima T, Zhang CY, Yamasaki R, Matsumoto K, Saito S (1992) Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn 39(4):355-363
96. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K (1995) In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 133(6):686-690
97. Marazuela M, Paniagua AE, Gahete MD, Lucas T, Alvarez-Escola C, Manzanares R, Cameselle-Teijeiro J, Luque-Ramirez M, Luque RM, Fernandez-Rodriguez E, Castano JP, Bernabeu I (2011) Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab 96(2):E251-E259
98. Mazal PR, Czech T, Sedivy R, Aichholzer M, Wanschitz J, Klupp N, Budka H (2001) Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol 20(4):163-171
99. Ahmed E, Stratton P, Adams W (1999) Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol 50(5):561-567
100. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol 58(1):86-91
101. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R (2006) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91(1):85-92
102. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF (2003) Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88(8):3567-3572
103. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152(3):379-387
104. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM (1997) Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82(10):3187-3191
105. Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R (2001) Failure of radiotherapy in acromegaly. Eur J Endocrinol 145(6):717-726
106. Izawa M, Hayashi M, Nakaya K, Satoh H, Ochiai T, Hori T, Takakura K (2000) Gamma knife radiosurgery for pituitary adenomas. J Neurosurg 93(Suppl 3):19-22
107. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G; Italian Multicenter Octreotide Study Group (1995) Effects of treatment with octreotide in acromegalic patients-a multicenter Italian study. Eur J Endocrinol 133(4):430-439
108. Bevan JS (2005) Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90(3):1856-1863
109. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ, Thorner MO (2003) Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 88(10):4759-4767
110. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, Melmed S (1992) Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 117(9):711-718
111. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87(7):3013-3018
112. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G, Giordano Disem G (1997) Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest 27(4):277-284
113. Abe T, Ludecke DK (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145(2):137-145
114. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91(6):2112-2118
115. Lucas T, Astorga R, Catala M (2003) Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol 58(4):471-481
116. Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G (2000) Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 143(5):577-584